This situation changed with the introduction of immunotherapeutics and targeted therapies for melanoma treatment, including antibody-based immunotherapeutic approaches that block the inhibitory CTLA4-CD80/CD86 and PD1-PD-L1 signaling axes apparent in all types of tumor progression (reviewed in [1]. Here, CD274 is linked to melanoma.